Koronyo-Hamaoui Lab

The primary focus of the Koronyo-Hamaoui Laboratory is on early diagnosis and immune-based therapies for Alzheimer's disease (AD). A feasible noninvasive test to identify patients early on, which is essential for effective treatment, is an urgent unmet need. The Koronyo-Hamaoui Laboratory has shown, for the first time, that the hallmark pathology of AD, amyloid-β protein (Aβ) plaque, is present in the retina of human patients beginning at early stages. Furthermore, a unique approach has been developed in this lab to detect plaques in the retina of live rodent models by a noninvasive optical retinal imaging. This innovation unveils new possibilities for investigation of Alzheimer's pathology in the retina. It may also facilitate early diagnosis and noninvasive monitoring of disease progression.

A large body of evidence accumulated over the past years suggested that the peripheral immune system plays a critical role in repair and regeneration of the central nervous system. This lab has demonstrated that harnessing peripheral immunity in murine transgenic models of AD via immune-modulating antigens, such as glatiramer acetate and MOG45D loaded on dendritic cells, stimulated recruitment of monocytes to the brain. This immunization approach leads to a reduction of harmful inflammation, toxic Aβ and scar tissue pathology, while restoring neurogenesis and cognitive functions. The lab further explores possibilities of utilizing inflammatory monocyte enrichment and the use of angiotensin-converting enzyme (ACE) overexpression in monocytes to counter AD progression. The Koronyo-Hamaoui team seeks to further identify and characterize new immunological mechanisms that help attenuate AD progression.

First Identification and Noninvasive Imaging of Pathological Hallmarks of AD: Aβ Plaques in the Retina

Left panels: The Koronyo-Hamaoui team has discovered the characteristic signs of Alzheimer’s disease in postmortem retinae of AD patients, including early-stage cases. Right panels: The lab has developed the first noninvasive high-resolution Aβ-plaque retinal imaging in living subjects. (Koronyo et al. JCI Insight 2017)


Meet Our Team

Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Koronyo-Hamaoui Laboratory, whose dedicated efforts lead to groundbreaking discoveries.

Shi H, Koronyo Y, Rentsendorj A, Regis GC, Sheyn J, Fuchs DT, Kramerov AA, Ljubimov AV, Dumitrascu OM, Rodriguez AR, Barron E, Hinton DR, Black KL, Miller CA, Mirzaei N, Koronyo-Hamaoui M.

Acta Neuropathologica. 2020;139(5), 813-836

Koronyo-Hamaoui M, Sheyn J, Hayden EY, Li S, Fuchs DT, Regis GC, Lopes DHJ, Black KL, Bernstein KE, Teplow DB, Fuchs S, Koronyo Y, Rentsendorj A.

Brain. 2019 pii: awz364.

Li, S, Hayden, EY, Garcia, VJ, Fuchs D-T, Sheyn, J, Daley DA, Rentsendorj, A, Torbati, T, Black, KL, Rutishauser, U, Teplow, DB, Koronyo Y, Koronyo-Hamaoui, M.

Frontiers in Immunology. 2020; 11:49.

Contact the Koronyo-Hamaoui Lab

Cedars-Sinai Maxine Dunitz Neurosurgical Institute
127 S. San Vicente Blvd.
Advanced Health Science Pavilion, Eighth Floor, Suite A8103
Los Angeles, CA 90048